Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Assets (2017 - 2025)

Vistagen Therapeutics' Return on Assets history spans 10 years, with the latest figure at 0.92% for Q4 2025.

  • For Q4 2025, Return on Assets fell 55.0% year-over-year to 0.92%; the TTM value through Dec 2025 reached 0.92%, down 55.0%, while the annual FY2025 figure was 0.49%, N/A changed from the prior year.
  • Return on Assets for Q4 2025 was 0.92% at Vistagen Therapeutics, down from 0.83% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.14% in Q1 2024 and bottomed at 1.29% in Q3 2023.
  • The 4-year median for Return on Assets is 0.37% (2024), against an average of 0.5%.
  • The largest annual shift saw Return on Assets surged 358bps in 2021 before it tumbled -57bps in 2025.
  • A 4-year view of Return on Assets shows it stood at 0.39% in 2021, then rose by 10bps to 0.35% in 2023, then fell by -6bps to 0.37% in 2024, then plummeted by -148bps to 0.92% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Return on Assets are 0.92% (Q4 2025), 0.83% (Q3 2025), and 0.73% (Q2 2025).